Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Sponsor: Celltrion
Summary
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
Official title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
512
Start Date
2024-01-11
Completion Date
2029-01
Last Updated
2024-05-22
Healthy Volunteers
No
Conditions
Interventions
CT-P53
Intravenous(IV) infusion
US-Ocrevus
Intravenous(IV) infusion
EU-Ocrevus
Intravenous(IV) infusion
Locations (1)
CT-P53 3.1 investigational site
Poznan, Poland